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Abstract
Vascular endothelia comprise a diverse population of cells that specialize in response to genetic
programs and environmental cues to take on distinct roles in different vessels, tissues, and organs,
and in response to pathophysiological stresses. Characterization of endothelial-cell diversity will
facilitate the development of novel, highly specific and safe therapies for many diseases. 
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The transition from an avascular embryo to a functional
organism requires the formation of a highly complex network
of capillary plexuses, blood vessels, and lymphatic vessels, in
order to meet the demands of every organ. The formation of
vessels in development and their later sprouting and remod-
eling are tightly regulated by an array of angiogenic and anti-
angiogenic factors interacting with multiple cells and tissues
[1,2]. Recent insights into these processes have led to a host
of potential therapeutic strategies to directly treat diseases
that are associated with too much angiogenesis (such as
cancer or inflammation) or too little (such as myocardial or
limb ischemia). Yet it is naive to assume that ‘broad-spectrum’
angiogenic or anti-angiogenic agents will be equally efficacious
and safe for all diseases, each of which may tend to affect
some vessels or organs more than others. Intuitively, it is
reasonable to surmise that endothelial cells that line vessels
in different organs have distinct functional and morphological
features and thus will require tailor-made therapies. This
presents a  daunting challenge for the design of targeted
approaches to prevent and/or treat disease. 
Logically, the first step is to characterize the molecular and
functional differences between endothelial cells in different
kinds of blood vessel or vascular ‘bed’. This is difficult,
however, because the molecular steps that result in tissue-
specific and organ-specific specialization of the vascular
network are among those that are least well understood.
Several groups have tried to delineate the molecular deter-
minants that distinguish endothelial cells in different vessels
and tissues, but the recent report by Chi et al. [3] is the first
to use microarray techniques on a ‘global’ scale. In this study
[3], the authors evaluated the expression profile of 53 cul-
tured human endothelial cell lines from veins, arteries and
microvessels from 14 different tissue sites. Not only did they
readily discern patterns of gene expression that could distin-
guish between the endothelial cells of large and small vessels
and between those of veins and arteries, but they also linked
the expression patterns of gene products from specialized
endothelia to functional roles that included regulation of
lipid transport, immune-cell migration, neurogenesis, tra-
cheal branching, and the establishment of the left/right
asymmetry of the body. Overall, they provide definitive
support for the notion that the transcriptional programs of
endothelial cells from different tissues and organs are specif-
ically adapted during development to assume distinct roles
at each site. 
Structural diversity of vascular endothelia
The concept of endothelial-cell heterogeneity in health and
disease is not a new one. The architecture of the tumor vas-
culature was recognized in the early 20th century as beingdistinct from that of normal tissue; tumor vasculature is
characterized by irregularly shaped, dilated, and tortuous
leaky vessels, often with associated hemorrhages. But how
much endothelial-cell heterogeneity exists in normal growth
and development? There is mounting evidence that endothe-
lial cells are extraordinarily diverse in their morphology,
function and gene-expression profile. Morphologically, they
differ in size, shape, thickness, number of microvilli, and
position of the nucleus. For example, aortic endothelial cells
are generally thicker but cover a smaller area than those
lining the pulmonary artery. Microvascular endothelial cells
from human placenta at the end of gestation are elongated,
whereas those from human umbilical veins are polygonal
[4]; this distinction is reflected functionally by differences in
their release of vasoactive substances and their interactions
with leukocytes [5]. 
The most prominent structural differences that impact on
function are in the apparent integrity of intercellular junc-
tional contacts; these have been recognized by physiologists
for many years. Small capillaries with tight, continuous junc-
tions are most evident in the central nervous system, provid-
ing protection to the brain from bacterial or toxic insults.
Somewhat thicker capillaries, also with continuous endothe-
lium, are typically found in skeletal tissue and in the heart,
testes and ovaries. Discontinuous endothelial cells, with
gaps of variable size between cells (fenestrations), allow effi-
cient transit of macromolecules and thus are predominant in
endocrine glands and the kidney. The factors that determine
the formation of tight junctions versus fenestrations are not
well understood, although occludins, claudins, zona occlu-
dens proteins, and the family of junctional adhesion mole-
cules are expressed in specific patterns in endothelial
venules, blood-brain barrier endothelial cells, and lymphatic
endothelial cells, contributing to the morphology and func-
tion of the intercellular contacts [6]. Recently, an endocrine-
gland specific angiogenic growth factor (EG-VEGF) was
isolated that is unrelated to the vascular endothelial growth
factor (VEGF) family and acts via G protein-coupled recep-
tors. EG-VEGF was found to cooperate with VEGF in the
formation of capillary fenestrations [7], a discovery that sup-
ports the hypothesis that a variety of yet-to-be-identified
growth factors regulate homotypic and heterotypic cell-cell
contacts as well as specificity of endothelial-cell differentia-
tion in different tissues. 
Early studies showed that antigen expression is similarly
diverse between endothelial cells in different organs and
tissues [8,9], and this has been confirmed more recently. For
example, the plasma glycoprotein von Willebrand factor is
prominent in veins, less prominent in arteries, and largely
absent from sinusoidal endothelial cells; the endothelial
protein C receptor is predominantly expressed by large vessel
endothelial cells [10]; and the cell-surface signaling proteins
ephrin-B2 and ephrin-B4 are specifically expressed by arter-
ies and veins, respectively [11]. The heart is particularly prone
to cytokine-induced recruitment of damaging subsets of
T lymphocytes; this may be partly attributed to higher
expression of the cell adhesion molecule VCAM-1 in myocar-
dial endothelial cells than in other organs [12]. 
Regulation of endothelial specialization
What are the mechanisms by which endothelial cells diver-
sify, and when does this occur? Is the endothelial cell pro-
grammed, or are there environmental elements that regulate
diversification and subsequent specificity? Environmental
factors clearly affect organogenesis, and cross-talk between
endothelial cells and the pericytes, stromal cells and extra-
cellular matrix that surround them are essential for their co-
ordinated function. This fact is highlighted by the finding that
a phenotype like that of the blood-brain barrier can be
induced in endothelial cells of non-brain origin by co-cultur-
ing them with astrocytes. This transformation, referred to as
‘barriergenesis’, is characterized by the formation of tight
junctions between endothelial cells, triggered by the expres-
sion of several molecules, including Src-suppressed C-kinase
substrate (SSeCKS), the platelet-derived growth factor
PDGF-BB, the angiogenic and antipermeability factor
angiopoieitin-1, its receptor Tie2, and the cell-adhesion mole-
cule N-cadherin, by surrounding glial cells [13]. In the retina,
an astrocyte ‘template’ is laid down prior to vascularization,
and interaction between R-cadherin molecules on astrocytes
and integrins and/or N-cadherins on endothelial cells or cir-
culating endothelial progenitor cells (CEPs) mediates growth
and migration of the vascular endothelium [14,15]. 
Although environmental cues appear to be critical for
endothelial-cell specialization, genetic programming is
equally important. It used to be generally believed that
arteries and veins developed differently in response to dif-
ferences in hemodynamic forces. Recent studies have
revealed, however, that the distinction between artery and
vein is determined during embryonic development, even
before blood is circulating, and that Notch signaling is one
of the crucial steps in determining the endothelial cell’s
phenotype. During vascular development, defects in signal-
ing through the Notch pathway - which comprises ligands
such as Jagged-1, Jagged-2, and Delta-like-4 and receptors
such as Notch-1, Notch-2, and Notch-4 - disrupt normal dif-
ferentiation into arteries or veins, resulting in loss of artery-
specific markers such as ephrin-B2 and ectopic expression
in the aorta of venous markers such as flt4 [16]. Conversely,
overactivation of Notch suppresses differentiation of vessels
to veins. Chi et al. [3] showed that Hey2, a transcription
factor that is induced by Notch signaling, confers features of
arterial endothelial-cell gene expression on vein-derived
endothelial cells, upregulating arterial-specific genes,
including ADHA1, EVA1, and keratin-7, while suppressing
vein-specific genes, such as GDF,  lefty-1 and  lefty-2.
Fishman and colleagues [17] established in zebrafish that
expression of the homolog of Hey2, gridlock, is required for
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defects in this pathway may be linked to morphogenic
abnormalities of the aorta. These findings appear to refute
the hypothesis that physiological cues are responsible for
artery and vein differentiation. Several studies suggest,
however, that even after endothelial cells attain a specific
arterial or venous phenotype late in embryonic develop-
ment, transdifferentiation may occur, and this process is
regulated in part by the vessel wall [18]. Thus, a complex
genetic program to regulate differentiation of endothelial
cells into arteries and veins may be modulated by extrinsic
factors, lending plasticity to the assembly and remodeling of
the vascular network in health and disease.
This type of interaction between a genetic program and envi-
ronmental factors may also hold for other kinds of endothe-
lial differentiation, not just the choice between arteries and
veins. Cells lining the endocardium and the coronary vessels
are derived from progenitor cells migrating from distinct
embryonic sites (reviewed in [19]). Fate-mapping studies
indicate that diversification of these clonal cells takes place
before their migration to the developing heart. Although this
suggests that the fate of a coronary-artery endothelial cell is
predetermined, the opportunities for the migrating cell to
interact with other cells and factors are considerable, and
thus diversification is likely to be a dynamic process, modi-
fied by intrinsic and extrinsic factors. 
Studies of lung development have shown that when isolated
lung rudiments with no blood vessels are implanted subcuta-
neously or underneath kidney capsules, they form lungs with
vasculature that - remarkably - develops by both vasculogen-
esis and angiogenesis, with the characteristic vascular and
alveolar network [20,21]. These findings support the concept
that there are genetic programs for the development of the
highly specific vasculatures but that these are modulated by
extrinsic factors provided by surrounding cells, the extracel-
lular matrix, and secreted growth factors and cytokines,
thereby providing both plasticity and diversity.
The phenotypic plasticity and diversity of endothelial cells is
not only manifest during embryonic development but is also
central to the normal function of several organs. This is
strikingly evident in the corpus luteum, a body that forms
from an egg follicle after the egg is released. Morphological
subtypes of microvascular endothelial cells in the corpus
luteum have been defined according to their shape (epithe-
lioid, spindle, round, or polygonal), the presence of cytoplas-
mic vacuoles, and the pattern of actin and vimentin filaments
[22]. Distinct populations of these cells are more or less
prominent at various stages of the monthly cycle of corpus
luteum formation and regression. Formation of the corpus
luteum includes a transient burst of angiogenesis, with
growth and proliferation of endothelial cells that express
high levels of cytokeratins, N-cadherin, and E-cadherin, and
establishment of a continuous, tight-junctioned vascular
network; this process is modulated by human chorionic
gonadotropin, vasoactive peptides, and cytokines. With sub-
sequent regression of the corpus luteum, the network is dis-
solved, as the endothelium transdifferentiates, yielding
disrupted, discontinous intercellular junctions. Permeability
increases, endothelial cells apoptose, capillaries regress
and/or become occluded, and the corpus luteum degenerates,
to prepare for the next cycle. Not only is this extraordinary
endothelial-cell plasticity and diversity crucial for the normal
luteal cycle, but endothelial cells from the corpus luteum of
pregnancy also exhibit unique lectin-binding properties, dis-
tinct from those seen in the non-pregnant state. 
The lymphatic circulation is composed of a network of thin-
walled, discontinuous capillaries that carry fluid, macromol-
ecules and immune cells. The extent of diversity of lymphatic
endothelial cells has yet to be evaluated, but any knowledge
of this may be important for our understanding of immune
surveillance and how tumor cells metastasize through the
lymphatic vessels [23]. Although the extrinsic and intrinsic
factors that regulate the formation of lymphatic vessels and
the specification of lymphatic organs and tissues are largely
unknown, it appears that expression of the Prox1 transcrip-
tion factor signals a switch in commitment from a venous
endothelial phenotype to a lymphatic one [24]. Transcrip-
tion-profiling studies of isolated cells have identified several
markers that are notably upregulated in lymphatic endothe-
lial cells compared with blood endothelial cells, including
Prox1, LYVE-1 (a marker of unknown function), the
chemokines  CCL21 and RANTES, stromal cell-derived
factor-1, and the angiogenesis regulator angiopoietin-2.
Angiogenic progenitors in therapeutic
angiogenesis
Accumulating evidence suggests that angiogenic progenitor
cells may be recruited from the bone marrow, circulation,
and other tissues, and these may contribute to new vessel
growth during normal development and after injury. In
response to an angiogenic stress, circulating endothelial
progenitor cells (CEPs) are mobilized, presumably from
endothelial precursor cells (EPCs), which are predominantly
located in the bone marrow. The CEPs proliferate and
migrate to the site of injury under the guidance of a variety
of factors, including VEGF, fibroblast growth factor 2,
soluble Kit ligand, and insulin-like growth factor (reviewed
in [25]). Although characterization of these progenitor cells
is incomplete, it is clear that as the CEPs mature, their
antigen expression pattern changes, with loss of the CD133
cell-surface marker (whose function is unknown) and acqui-
sition of markers specific to the target tissue. Thus, for
example, CEPs with a lymphatic-vessel fate upregulate
expression of the VEGF receptor 3. 
Major advances have been made in delineating the molecu-
lar mechanisms that regulate the processes that ultimately
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vessels. Indeed, preclinical trials have been initiated to use
transplantation of angiogenic progenitor cells to enhance
tissue revascularization of damaged heart, limb and retina.
Yet potential hurdles remain. The degree to which CEPs can
adapt to different vascular beds, in a variety of pathological
states, is entirely unknown [26]. The heterogeneity of the
vasculature and the complex regulation of specialization of
the endothelium may hinder effective incorporation of trans-
planted CEPs. For example, injured tissue may fail to
provide appropriate organ-specific or tissue-specific envi-
ronmental cues to ensure transdifferentiation of CEPs into
functionally mature and competent endothelial cells. In the
worst case, this may yield abnormal, non-functional, bleed-
ing or thrombosis-prone vessels in undesirable locations,
and furthermore it may exacerbate disease at other sites.
Nonetheless, vascular endothelial progenitor-cell therapies
hold great promise. Characterization of the factors that regu-
late the differentiation and specialization of EPCs, CEPs, and
mature endothelium will facilitate safe introduction of this
novel and exciting technology to the clinic.
With wide acceptance that the vascular endothelium is com-
posed of cells with considerable heterogeneity, several
groups have devised novel methods to identify tissue-
specific receptors that might be used therapeutically. Differ-
ential molecular phenotyping of endothelial cells from
normal and tumor tissue using serial analysis of gene
expression (SAGE) technology has revealed the expression
of novel tumor-specific endothelial markers [27]. Differen-
tial-display technologies have been used to distinguish the
gene profiles of endothelial cells under shear stress, demon-
strating that this stress induces expression of protective anti-
oxidant, anti-apoptotic and anti-proliferative genes [28].
Using phage-display of random peptide libraries, peptide
ligands have been isolated that recognize endothelial cells
from specific tissues or organs, including the breast, lung,
prostate, and heart, and this technique may be expanded to
map the expression profile of the vasculature under different
stresses [29]. The results of such studies have been exploited
by linking pro-apoptotic factors to the peptides so as to
selectively destroy murine prostate tumors [30]. In experi-
mental models, other agents, including neutralizing antibod-
ies and cytotoxic drugs, have similarly been targeted to
vascular endothelial cells in specific tissues to block tumor
angiogenesis, interfere with retinal neovascularization, and
to suppress the chronic inflammation associated with arthri-
tis (reviewed in [29]). 
The complexity and heterogeneity of the vascular endothe-
lium, once viewed as an inert conduit to simply carry blood,
is astounding. With enhanced computer database manage-
ment, the development of high-throughput in vivo screening
methods, and paradigms to explore the diversity of endothe-
lial cells, smooth muscle cells and extracellular matrix under
a variety of pathophysiological conditions using in vivo
experimental models, the stage is set for the development of
safer, more effective and targeted therapies for the many dis-
eases associated with vascular dysfunction. 
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